Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib
Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib
Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib
Submitted by
admin
on October 21, 2013 - 5:55pm
Source:
Fierce Biotech
News Tags:
Novartis
cyclin-dependent kinase inhibition [CDK]
Pfizer
palbociclib
LEE011
Headline:
Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib
Do Not Allow Advertisers to Use My Personal information
